| Biomarker ID | 307 |
| PMID | 18553995 |
| Year | 2008 |
| Biomarker | Nucleophosmin (NPM) (Nucleolar phosphoprotein B23) (Numatrin) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated (Mean Ratio: 2.6 ±1.01) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Deposition of new CENP-A-containing nucleosomes at the centromere,HIF-1 transcriptional activity in hypoxia,BARD1 signaling events,Aurora B signaling, Interactions of HIV Vpr protein with host cellular proteins |
| Experiment | Prostate cancer Vs Benign Prostatic Hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | 20 patients were chosen for the study. 10 patients with Prostate Cancer and 10 patients with benign prostatic hyperplasia (BPH). |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p≤0.01 |
| Method Used | Isobaric tag for relative and absolute quantitation (iTRAQ) , two-dimensional liquid chromatography-tandem mass spectrometry (2DLC-MS/MS) |
| Clinical | No |
| Remarks | Mean ratio corresponds to the protein reporter ion intensity originating from PCa relative to BPH. Immunohistochemistry was performed on selected genes- PSMA, AMACR, and MUC18 to confirm iTRAQ results |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NPM1 |